Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Identify buffer targets, automate savings, and simulate scenarios to ensure your budget remains steady when unexpected costs arise.
19,303 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
AMD signals a shift from pure CPUs to AI acceleration, blending edge and cloud compute. This article breaks down what...
When a board member sells 7,000 shares, traders and long-term investors want to know why. This article breaks down Fo...
AST SpaceMobile has fallen from its highs even after a sizable funding round. This article explains why the fade in s...
Housing equity for Americans aged 62 and older hit a new high in the first quarter of 2026, driven by rising home val...
A disciplined foundation reshapes its tech-payments exposure by boosting its stake in Shift4 Payments. This article e...
You’ve bought a few rental properties, but the real work starts now. This guide delivers a step-by-step plan to optim...
February can test nerves, but smart stock selection pays off. Here are two robust candidates that align with the curr...
As Alphabet treads into 2026, three driving forces could shape its trajectory: AI-powered growth, smarter ads monetiz...
RedotPay, a hong kong-based stablecoin payments company, is weighing a U.S. IPO that could raise more than $1 billion...
Anchorage Digital confirms it holds Strategy’s STRC perpetual preferred stock, marking a high-profile move by a regul...
A major partnership reshapes Novo Nordisk's growth trajectory. This deep dive explains what the Vivtex deal means for...